CD44 and breast carcinoma: To evaluate the CSC properties in MCF7 and doxo-resistant MCF7/ADR cells, we first evaluated the population of CD44+/CD24- and ALDH+ cells, which have been reported as the best markers for identification of breast cancer stem cells [5, 15].